EE9700345A - Inimese CB2 retseptori agonistühendite kasutamine immunomoduleerivate ravimite, uute inimese CB2 retseptori agonistide ja neid sisaldavate farmatseutiliste kompositsioonide valmistamiseks - Google Patents
Inimese CB2 retseptori agonistühendite kasutamine immunomoduleerivate ravimite, uute inimese CB2 retseptori agonistide ja neid sisaldavate farmatseutiliste kompositsioonide valmistamiseksInfo
- Publication number
- EE9700345A EE9700345A EE9700345A EE9700345A EE9700345A EE 9700345 A EE9700345 A EE 9700345A EE 9700345 A EE9700345 A EE 9700345A EE 9700345 A EE9700345 A EE 9700345A EE 9700345 A EE9700345 A EE 9700345A
- Authority
- EE
- Estonia
- Prior art keywords
- group
- alkyl
- hydrogen
- halogen
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9507438A FR2735774B1 (fr) | 1995-06-21 | 1995-06-21 | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
PCT/FR1996/000959 WO1997000860A1 (fr) | 1995-06-21 | 1996-06-20 | Composes agonistes du recepteur cb¿2? |
Publications (1)
Publication Number | Publication Date |
---|---|
EE9700345A true EE9700345A (et) | 1998-06-15 |
Family
ID=9480236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EE9700345A EE9700345A (et) | 1995-06-21 | 1996-06-20 | Inimese CB2 retseptori agonistühendite kasutamine immunomoduleerivate ravimite, uute inimese CB2 retseptori agonistide ja neid sisaldavate farmatseutiliste kompositsioonide valmistamiseks |
Country Status (30)
Country | Link |
---|---|
US (1) | US6013648A (tr) |
EP (1) | EP0833818B1 (tr) |
JP (1) | JP3417566B2 (tr) |
KR (1) | KR19990028272A (tr) |
CN (1) | CN1150166C (tr) |
AT (1) | ATE207054T1 (tr) |
AU (1) | AU717858B2 (tr) |
BR (1) | BR9608640A (tr) |
CA (1) | CA2225379A1 (tr) |
CZ (1) | CZ292630B6 (tr) |
DE (1) | DE69616056T2 (tr) |
DK (1) | DK0833818T3 (tr) |
EE (1) | EE9700345A (tr) |
ES (1) | ES2165986T3 (tr) |
FR (1) | FR2735774B1 (tr) |
HK (1) | HK1005093A1 (tr) |
HU (1) | HUP9900019A3 (tr) |
IL (1) | IL122637A0 (tr) |
IS (1) | IS4637A (tr) |
MX (1) | MX9710251A (tr) |
NO (1) | NO975989L (tr) |
NZ (1) | NZ312161A (tr) |
PL (1) | PL185598B1 (tr) |
PT (1) | PT833818E (tr) |
RU (1) | RU2200736C2 (tr) |
SI (1) | SI0833818T1 (tr) |
SK (1) | SK283660B6 (tr) |
TR (1) | TR199701660T1 (tr) |
UA (1) | UA67717C2 (tr) |
WO (1) | WO1997000860A1 (tr) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2735774B1 (fr) * | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
EP1075470B1 (en) * | 1998-05-04 | 2003-08-13 | The University Of Connecticut | Novel analgesic and immunomodulatory cannabinoids |
ATE277921T1 (de) * | 1998-05-04 | 2004-10-15 | Univ Connecticut | Selektiv auf den cb2-rezeptor wirkende cannabinoide |
US7897598B2 (en) | 1998-06-09 | 2011-03-01 | Alexandros Makriyannis | Inhibitors of the anandamide transporter |
US7589220B2 (en) | 1998-06-09 | 2009-09-15 | University Of Connecticut | Inhibitors of the anandamide transporter |
DE19837627A1 (de) * | 1998-08-19 | 2000-02-24 | Bayer Ag | Neue Aminosäureester von Arylsulfonamiden und Analoga |
US7276613B1 (en) | 1998-11-24 | 2007-10-02 | University Of Connecticut | Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
US7161016B1 (en) | 1998-11-24 | 2007-01-09 | University Of Connecticut | Cannabimimetic lipid amides as useful medications |
US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
GB9923314D0 (en) * | 1999-10-01 | 1999-12-08 | Pfizer Ltd | Acylation process |
EP1702617A1 (en) * | 1999-10-18 | 2006-09-20 | The University Of Connecticut | Cannabimimetic indole derivatives |
US8084467B2 (en) | 1999-10-18 | 2011-12-27 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
US7393842B2 (en) | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
MXPA02005101A (es) * | 1999-10-18 | 2003-09-25 | Alexipharma Inc | Derivados de indol canabimimeticos. |
US7119108B1 (en) | 1999-10-18 | 2006-10-10 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
WO2001028329A1 (en) | 1999-10-18 | 2001-04-26 | University Of Connecticut | Peripheral cannabinoid receptor (cb2) selective ligands |
US7741365B2 (en) | 1999-10-18 | 2010-06-22 | University Of Connecticut | Peripheral cannabinoid receptor (CB2) selective ligands |
US6900236B1 (en) | 1999-10-18 | 2005-05-31 | University Of Connecticut | Cannabimimetic indole derivatives |
US6943266B1 (en) * | 1999-10-18 | 2005-09-13 | University Of Connecticut | Bicyclic cannabinoid agonists for the cannabinoid receptor |
IL132661A (en) * | 1999-10-31 | 2008-11-26 | Raphael Mechoulam | Agonists specific for peripheral cannabinoid receptors |
AU2001234958A1 (en) * | 2000-02-11 | 2001-08-20 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
CA2410401A1 (en) * | 2000-05-23 | 2001-11-29 | Daniele Piomelli | A novel treatment for cough |
AU7705601A (en) | 2000-07-25 | 2002-02-05 | Merck & Co Inc | N-substituted indoles useful in the treatment of diabetes |
US6541510B2 (en) * | 2000-09-28 | 2003-04-01 | Immugen Pharmaceuticals, Inc. | Antiviral methods and compounds |
WO2002026224A2 (en) * | 2000-09-28 | 2002-04-04 | Immugen Pharmaceuticals, Inc. | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation |
FR2814678B1 (fr) * | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
AUPR118000A0 (en) * | 2000-11-02 | 2000-11-23 | Amrad Operations Pty. Limited | Therapeutic molecules and methods |
FR2816938B1 (fr) * | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant |
EP1361876A4 (en) | 2001-01-26 | 2004-03-31 | Univ Connecticut | NEW CANNABIMIMETIC LIGANDS |
EP1363632B1 (en) * | 2001-01-29 | 2010-08-25 | The University of Connecticut | Receptor selective cannabimimetic aminoalkylindoles |
US7067539B2 (en) * | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
US7507767B2 (en) * | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
EP1414775B1 (en) * | 2001-07-13 | 2012-12-19 | The University of Connecticut | Bicyclic cannabinoid |
BR0211251B1 (pt) * | 2001-07-18 | 2013-09-17 | composição para o tratamento de cabelo e/ou couro cabeludo. | |
WO2003035005A2 (en) | 2001-10-26 | 2003-05-01 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
RU2004117907A (ru) | 2001-11-14 | 2006-01-10 | Шеринг Корпорейшн (US) | Лиганды каннабиноидных рецепторов |
TW200407110A (en) * | 2001-11-23 | 2004-05-16 | Astrazeneca Ab | New use for the treatment of gastroesophageal reflux disease |
EP1461027A4 (en) * | 2001-12-07 | 2005-09-07 | Univ Virginia Commonwealth | TREATMENT OF NEOPLASIA |
US7632955B2 (en) * | 2001-12-13 | 2009-12-15 | National Health Research Institutes | Indole compounds |
US7528165B2 (en) * | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
US6933316B2 (en) * | 2001-12-13 | 2005-08-23 | National Health Research Institutes | Indole compounds |
US20040171613A1 (en) * | 2001-12-27 | 2004-09-02 | Japan Tobacco Inc. | Therapeutic agent for non-immediate type allergic diseases |
WO2003061699A1 (fr) * | 2001-12-27 | 2003-07-31 | Japan Tobacco, Inc. | Remedes pour affections allergiques |
MXPA04007414A (es) | 2002-02-01 | 2004-10-11 | Hoffmann La Roche | Indoles sustituidos como agonistas alfa-1. |
WO2003070277A1 (fr) | 2002-02-19 | 2003-08-28 | Shionogi & Co., Ltd. | Antiprurigineux |
US7351729B2 (en) | 2002-03-08 | 2008-04-01 | Signal Pharmaceuticals, Llc | JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers |
CN1652766A (zh) * | 2002-03-18 | 2005-08-10 | 免疫力药品有限公司 | 间苯二酚和大麻素的局部制剂及其施用方法 |
FR2839718B1 (fr) * | 2002-05-17 | 2004-06-25 | Sanofi Synthelabo | Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant |
US7217732B2 (en) | 2002-06-19 | 2007-05-15 | Schering Corporation | Cannabinoid receptor agonists |
AU2003265663A1 (en) | 2002-08-23 | 2004-03-11 | University Of Connecticut | Keto cannabinoids with therapeutic indications |
JP4455339B2 (ja) | 2002-11-25 | 2010-04-21 | シェーリング コーポレイション | カンナビノイドレセプターリガンド |
AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
EP1644370A4 (en) | 2003-07-11 | 2008-06-04 | Bristol Myers Squibb Co | TETRAHYDROCHINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS |
US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
IL160420A0 (en) | 2004-02-16 | 2004-07-25 | Yissum Res Dev Co | Treating or preventing diabetes with cannabidiol |
CN101005838A (zh) * | 2004-06-22 | 2007-07-25 | 先灵公司 | 大麻素受体配体 |
US7517991B2 (en) * | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
EP1833824B1 (en) | 2004-12-21 | 2016-08-03 | AbbVie Inc. | 3-cycloalkylcarbonyl indoles as cannabinoid receptor ligands |
US7456289B2 (en) * | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
FR2893615B1 (fr) | 2005-11-18 | 2008-03-07 | Sanofi Aventis Sa | Derives de 3-acylindole, leur preparation et leur application en therapeutique |
US7875639B2 (en) | 2006-05-31 | 2011-01-25 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
US8841334B2 (en) | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
EP2142522A1 (en) | 2007-03-28 | 2010-01-13 | Abbott Laboratories | 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands |
US7872033B2 (en) | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
MX2009012374A (es) | 2007-05-18 | 2009-12-01 | Abbott Lab | Compuestos novedosos como ligandos del receptor de canabinoides. |
US7943658B2 (en) | 2007-07-23 | 2011-05-17 | Bristol-Myers Squibb Company | Indole indane amide compounds useful as CB2 agonists and method |
US9193713B2 (en) | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
FR2933697B1 (fr) | 2008-07-11 | 2010-08-13 | Sanofi Aventis | Derives de 1-benzyl-cinnolin-4-(1h)-one substitues, leur preparation et leur application en therapeutique |
US8846730B2 (en) | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
TW201016692A (en) | 2008-09-16 | 2010-05-01 | Abbott Lab | Novel compounds as cannabinoid receptor ligands |
PA8854001A1 (es) | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
EP2456428A1 (en) | 2009-07-23 | 2012-05-30 | INSERM - Institut National de la Santé et de la Recherche Médicale | Selective cb2 receptor agonists for use in the prevention or treatment of alcoholic liver disease |
FR2950055A1 (fr) | 2009-09-17 | 2011-03-18 | Sanofi Aventis | Derives de 3-amino-cinnolin-4(1h)-one substitues, leur preparation et leur application en therapeutique |
EP2606032B1 (en) | 2010-08-20 | 2015-01-07 | University Of Washington Through Its Center For Commercialization | Composition and methods for treating glioblastomas |
CA2822357A1 (en) | 2010-12-22 | 2012-06-28 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
FR2983859B1 (fr) | 2011-12-12 | 2014-01-17 | Sanofi Sa | Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique |
WO2013106349A1 (en) * | 2012-01-09 | 2013-07-18 | The Board Of Trustees Of The University Of Arkansas | Use of the aminoalkylindole jwh-073-m4 and related compounds as neutral cb1 recptor antagonists for the treatment of alcoholism, drug abuse, obesity, and obesity-related diseases |
WO2014015298A1 (en) | 2012-07-20 | 2014-01-23 | The Regents Of The University Of California | Peripherally-acting cannabinoid receptor agonists for chronic pain |
KR20150102511A (ko) * | 2014-02-28 | 2015-09-07 | 주식회사 아세아텍 | 베일러용 드로우 |
CZ306547B6 (cs) * | 2014-12-31 | 2017-03-01 | Vysoká škola chemicko - technologická v Praze | Derivát syntetického kanabinoidu, způsob jeho přípravy a použití |
CZ2014985A3 (cs) * | 2014-12-31 | 2016-03-09 | Vysoká škola chemicko- technologická v Praze | Derivát syntetického kanabinoidu, způsob jeho přípravy a použití |
CN109715152A (zh) * | 2016-04-29 | 2019-05-03 | 柯巴斯医药有限公司 | 医治感染的方法 |
CN108794379A (zh) * | 2017-04-26 | 2018-11-13 | 华东师范大学 | 1h-吲哚-2-甲酰胺衍生物及其制备方法和应用 |
AU2019210332A1 (en) | 2018-01-22 | 2020-09-10 | Pascal Biosciences Inc. | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells |
IL295374A (en) | 2020-02-04 | 2022-10-01 | Mindset Pharma Inc | 3-pyrrolidine indole derivatives as serotonergic psychedelics for the treatment of central nervous system disorders |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RO77049A2 (ro) * | 1980-08-08 | 1981-06-22 | Institutul De Cercetari Chimico-Farmaceutice,Ro | Derivati de 2-metil-3-etilindol si procedeu de preparare a acestora |
RO90049A2 (ro) * | 1984-12-25 | 1986-08-30 | Centrala Industriala De Medicamente Cosmetice,Coloranti Si Lacuri,Ro | Procedeu de preparare a clorhidratului hidrat de 1-(p-clorbenzoil)3-/2-(di-n-propilamino) etil/5-metoxi-2-metilindol |
US5068234A (en) * | 1990-02-26 | 1991-11-26 | Sterling Drug Inc. | 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles |
US5081122A (en) * | 1990-03-05 | 1992-01-14 | Sterling Drug Inc. | Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof |
US4973587A (en) * | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
US5013837A (en) * | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
FR2735774B1 (fr) * | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
-
1995
- 1995-06-21 FR FR9507438A patent/FR2735774B1/fr not_active Expired - Fee Related
-
1996
- 1996-06-20 PL PL96324185A patent/PL185598B1/pl not_active IP Right Cessation
- 1996-06-20 IL IL12263796A patent/IL122637A0/xx not_active IP Right Cessation
- 1996-06-20 CN CNB961961260A patent/CN1150166C/zh not_active Expired - Fee Related
- 1996-06-20 MX MX9710251A patent/MX9710251A/es not_active IP Right Cessation
- 1996-06-20 AU AU63632/96A patent/AU717858B2/en not_active Ceased
- 1996-06-20 SI SI9630401T patent/SI0833818T1/xx unknown
- 1996-06-20 UA UA97126177A patent/UA67717C2/uk unknown
- 1996-06-20 EE EE9700345A patent/EE9700345A/xx unknown
- 1996-06-20 EP EP96922962A patent/EP0833818B1/fr not_active Expired - Lifetime
- 1996-06-20 KR KR1019970709586A patent/KR19990028272A/ko active IP Right Grant
- 1996-06-20 JP JP50362997A patent/JP3417566B2/ja not_active Expired - Fee Related
- 1996-06-20 NZ NZ312161A patent/NZ312161A/xx unknown
- 1996-06-20 AT AT96922962T patent/ATE207054T1/de not_active IP Right Cessation
- 1996-06-20 ES ES96922962T patent/ES2165986T3/es not_active Expired - Lifetime
- 1996-06-20 DE DE69616056T patent/DE69616056T2/de not_active Expired - Fee Related
- 1996-06-20 CZ CZ19974143A patent/CZ292630B6/cs not_active IP Right Cessation
- 1996-06-20 TR TR97/01660T patent/TR199701660T1/tr unknown
- 1996-06-20 CA CA002225379A patent/CA2225379A1/en not_active Abandoned
- 1996-06-20 PT PT96922962T patent/PT833818E/pt unknown
- 1996-06-20 BR BR9608640A patent/BR9608640A/pt not_active Application Discontinuation
- 1996-06-20 WO PCT/FR1996/000959 patent/WO1997000860A1/fr active IP Right Grant
- 1996-06-20 DK DK96922962T patent/DK0833818T3/da active
- 1996-06-20 SK SK1735-97A patent/SK283660B6/sk unknown
- 1996-06-20 HU HU9900019A patent/HUP9900019A3/hu unknown
- 1996-06-20 RU RU98101097/14A patent/RU2200736C2/ru not_active IP Right Cessation
-
1997
- 1997-12-19 IS IS4637A patent/IS4637A/is unknown
- 1997-12-19 NO NO975989A patent/NO975989L/no not_active Application Discontinuation
- 1997-12-22 US US08/995,902 patent/US6013648A/en not_active Expired - Fee Related
-
1998
- 1998-05-19 HK HK98104304A patent/HK1005093A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE9700345A (et) | Inimese CB2 retseptori agonistühendite kasutamine immunomoduleerivate ravimite, uute inimese CB2 retseptori agonistide ja neid sisaldavate farmatseutiliste kompositsioonide valmistamiseks | |
NO982330L (no) | Pyrazolderivater, fremgangsmÕte for fremstilling derav og farmas°ytiske preparater inneholdende nevnte derivater | |
DE69813896D1 (de) | Alpha-aminoamidderivate die als analgetische mittel nützlich sind | |
HUP0300922A2 (hu) | Új vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
EA200600364A1 (ru) | Производные (тио)карбамоилциклогексана в качестве антагонистов d/dрецептора | |
HUP0303652A2 (hu) | Ciklikus származékok, mint kemokin receptor aktivitás modulátorai és ezeket tartalmazó gyógyszerkészítmények | |
HUP9901613A2 (hu) | Szubsztituált tetraciklusos kondenzált furán-amin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
HUP0402261A2 (hu) | Piperidinszármazékok és alkalmazásuk kemokin receptor aktivitás modulátoraiként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0302968A2 (hu) | (Aminoalkilbenzoil)benzofuránok vagy -benzotiofének, eljárás a vegyületek előállítására és a vegyületeket tartalmazó készítmények | |
WO2002034754A3 (en) | Benzoxazinone derivatives, their preparation and use | |
IL83681A0 (en) | Dihydropyridines,their preparation and pharmaceutical compositions containing them | |
HUP9801386A2 (hu) | Szerotonin 5-HT4 receptor parciális agonistáiként és antagonistáiként alkalmazható indazol-karboxamid-származékok, előállításuk és alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények | |
IL108969A0 (en) | Substituted (arylalkoxybenzyl) aminopropionamide derivatives, their preparation and pharmaceutical compositions containing them | |
ES8207525A1 (es) | Un procedimiento para la preparacion de nuevos derivados de la quinoleina. | |
HUP9602763A2 (hu) | 3-Fenil-izoxazol-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítmények | |
DK485489A (da) | Amider og nitriler, framaceutiske praeparater indeholdende disse og anvendelse af forbindelserne til fremstilling af laegemidler | |
WO1999021848A3 (en) | Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands | |
ES483162A1 (es) | Un procedimiento para peparar nuevas ureas sustituidas. | |
HUP0204149A2 (hu) | Új szulfoniloxazolamin-származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás a vegyületek előállítására | |
HUP0400744A2 (hu) | Piridoindolon származékok felhasználása rákellenes gyógyszerek előállítására | |
DK1351942T3 (da) | Nye 2,3-benzodiazepinderivater og farmaceutiske sammensætninger indeholdende disse som den aktive bestanddel | |
DK0765322T3 (da) | Indolderivater som pro-drugs for 5-HT1-lignende receptoragonister | |
SE7701843L (sv) | Forfarande for framstellning av nya derivat av ditiepino-(1,4)(2,3-c)-pyrrol | |
HUP0401345A2 (hu) | Új triciklusos dihidrokinolin vegyületek, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények |